Reviewer’s report

Title: Cost-minimization analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement

Version: 1 Date: 15 September 2010

Reviewer: Marie-Christine WORONOFF-LEMSI

Reviewer’s report:

The paper reports an economic analysis based on retrospective data collected from two hospitals during four years. The study is limited to Hong Kong area. Only data from 60 consecutive patients were collected from two hospitals and four years. This is limited recruitment for a period of four years.

1- Short Presentation of the US model demonstrated cost-effectiveness of Xelox [ref 27] is needed, (meeting abstract ?);
2- the analysis is conducted on both the healthcare provider & societal perspectives. Have self-financed part of both chemotherapy regimens (XELOX & OXA )an assessable impact on the population use of care ? The patient perspective could be very interesting.
3- The authors assess the need of cost-effectiveness evidence as a component of drug evaluation for inclusion into HA drug formulary. Do your paper change something ?
4- Why data were not bootstrapped in order to allow statistical testing ?

Minor comments

6- The paper needs to present cost data and results into US$ or € to be more suitable (even if exchange rate was presented in sensitivity analysis)
7- Is it sure that all references (42) are needed ?

Level of interest: An article of limited interest

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

In the past five years, I receive reimbursement from ROCHE France to participate in a board on Pharmacoeconomics in France.